A 1 μl volume of 10 mM cavtratin, a peptide containing the Cav1 scaffolding domain, or the control peptide AP, was injected into the vitreous chamber 4 hr before the ocular hypertension treatment. Here, CAV1 is linked to ocular hypertension.